Andrea Marias Furuya
Research Subjects
Research Interests
Andrea Marias Furuya has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Danushka K. Wijesundara
Vaxxas Biomedical Facility, Hamilton, QLD 4007, Australia
2 shared publications Clare M Williams
Department of Immunology and Microbial Disease Albany Medical College Albany NY USA
1 shared publication- Clare Williams
Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA
1 shared publication Sreeja Roy
Department of Immunology and Microbial Disease Albany Medical College Albany NY USA
1 shared publicationWei Sun
Department of Immunology and Microbial Disease Albany Medical College Albany NY USA
1 shared publication- Wei Sun
Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY, 12208, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Wiley in Clinical & Translational Immunology
- Vol. 11 (3) , e1381
LUNG group 2 innate lymphoid cells as a new adjuvant target to enhance intranasal vaccine efficacy against influenza
Group 2 innate lymphoid cells (ILC2) are a relatively new class of innate immune cells. Lung ILC2 are early responders that secrete type 2 cytokines in response to danger ‘alarmin’ signals such as interleukin (IL)‐33 and thymic stromal lymphopoietin. Being an early source of type 2 cytokines, ILC2 are a critical regulator of type 2 immune cells of both innate and adaptive immune responses. The immune regulatory functions of ILC2 were mostly investigated in diseases where T helper 2 inflammation predominates. However, in recent years, it has been appreciated that the role of ILC2 extends to other pathological conditions such as cancer and viral infections. In this review, we will focus on the potential role of lung ILC2 in the induction of mucosal immunity against influenza virus infection and discuss the potential utility of ILC2 as a target for mucosal vaccination.
- 1 January 2022
- Published by Wiley in Clinical & Translational Immunology
- Vol. 11 (3) , e1381
Open AccessLUNG group 2 innate lymphoid cells as a new adjuvant target to enhance intranasal vaccine efficacy against influenza
Group 2 innate lymphoid cells (ILC2) are a relatively new class of innate immune cells. Lung ILC2 are early responders that secrete type 2 cytokines in response to danger ‘alarmin’ signals such as interleukin (IL)‐33 and thymic stromal lymphopoietin. Being an early source of type 2 cytokines, ILC2 are a critical regulator of type 2 immune cells of both innate and adaptive immune responses. The immune regulatory functions of ILC2 were mostly investigated in diseases where T helper 2 inflammation predominates. However, in recent years, it has been appreciated that the role of ILC2 extends to other pathological conditions such as cancer and viral infections. In this review, we will focus on the potential role of lung ILC2 in the induction of mucosal immunity against influenza virus infection and discuss the potential utility of ILC2 as a target for mucosal vaccination.
- Open Access
Fear of Influenza Resurgence amid COVID-19 Pandemic: Need for Effective Flu Vaccine Still Exists
As influenza season was approaching in 2020, public health officials feared that influenza would worsen the COVID-19 situation
Open AccessFear of Influenza Resurgence amid COVID-19 Pandemic: Need for Effective Flu Vaccine Still Exists
As influenza season was approaching in 2020, public health officials feared that influenza would worsen the COVID-19 situation